Valeant Pharma (VRX) Reports Q3 EPS of $0.14; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results
October 19, 2015 6:00 AM EDTLAVAL, Quebec, Oct. 19, 2015 /PRNewswire/ --
2015 Third Quarter Results
Total Revenues of $2.8 billion; an increase of 36% over the prior year despite negative foreign exchange impact of $172 million Same store sales organic growth of 13%; 5th consecutive quarter of > 10% organic growth, driven by: Continued outperformance of U.S. businesses, particularly dermatology and contact lens Strong results in China (23%), South Korea (15%) and Mexico (10%) Total company growth was 8.2% volume and 4.4% price U.S. branded pharmaceuticals growth was 18.8% volume... More